Inside every cell in your body, there are between 100 and 2,000 mitochondria, tiny organelles that produce ATP, the energy currency of life. But mitochondria are also a source of problems: they leak free radicals, their DNA accumulates damage, and when they malfunction, they become more harmful than beneficial. Nature solved this problem over 500 million years ago with an elegant mechanism: mitophagy, a process where the cell identifies damaged mitochondria, wraps them in a membrane, and breaks them down into their components.
On May 15, 2026, The Manila Times published a report on a new grant from the Countdown Grant Foundation that will fund dedicated research on mitophagy. The foundation views mitophagy as the bottleneck of aging medicine: according to its founders, mitophagy failure is the earliest mechanical cause of Parkinson's, heart disease, kidney disease, and broad symptoms of aging in every tissue. The link between mitophagy and aging is becoming one of the most active frontiers in biotechnology in 2026, with competition among companies to develop the first FDA-approved 'mitophagy enhancer'.
What is Mitophagy?
The word mitophagy is a combination of mitochondrion and phagos (to eat in Greek). In practice, it is a process where the cell performs specific 'garbage collection' for damaged mitochondria:
- Identification, the cell identifies which mitochondrion has lost its membrane potential (low Δψm) or is accumulating oxidative damage.
- Tagging, special proteins, mainly PINK1 and Parkin, settle on the damaged mitochondrion and tag it with a ubiquitin chain.
- Wrapping, a double membrane (autophagosome) closes around the tagged mitochondrion.
- Breakdown, the autophagosome fuses with a lysosome, and hydrolytic enzymes break down the mitochondrion.
- Recycling, the components are sent to build new mitochondria (along with the biogenesis process via PGC-1α).
In a young cell, the process operates continuously. About 1-2% of the mitochondrial mass is replaced each day. In an elderly cell, the rate drops by 3 to 5 times. The result: older, less efficient mitochondria that leak more ROS.
The Link Between Mitophagy and Aging: The PINK1-Parkin Pathway
At the center of the story is one biochemical pathway that scientists have deciphered over the last 15 years. It is called PINK1-Parkin, after its two main proteins, and it served as the first source of understanding that defective mitophagy causes human disease.
PINK1 (PTEN-Induced Kinase 1) is the defect sensor. Normally, it enters a healthy mitochondrion and is quickly broken down. But when the mitochondrion has lost its membrane potential, PINK1 cannot enter, remains on the outer membrane, and accumulates there. It functions as a red flag.
This flag recruits Parkin, an E3 ubiquitin ligase enzyme. Parkin begins to attach ubiquitin to proteins on the outer membrane of the mitochondrion. These ubiquitin chains are the 'label' that tells the autophagy system: 'this organelle needs to be removed'.
The discovery of this pathway came from research on early-onset Parkinson's. People with inherited mutations in PINK1 or Parkin develop Parkinson's before age 40. The reason: their dopamine neurons, which rely on particularly high-quality mitochondria, accumulate damaged mitochondria and die early in life. The notion that 'Parkinson's is a disease of mitophagy' began here and spread to other diseases.
With age, even without a mutation, levels of PINK1 and Parkin decrease. A cross-sectional study in Cell Reports from 2023 showed that PINK1 expression in the human brain decreases by about 40% between ages 30 and 70. This means that even without a genetic disease, the system for removing damaged mitochondria gradually deteriorates.
Current Evidence
Study 1: Urolithin A in Healthy Older Adults, Mitopure by Amazentis, 2022-2025
The world's first clinical trial of a mitophagy enhancer in humans was conducted by the Swiss company Amazentis. Urolithin A, a metabolite produced by the gut microbiome from ellagitannins (compounds found in pomegranates and walnuts), was found to activate mitophagy via the PINK1-Parkin pathway. A trial on 88 older adults aged 65-90 who took 500 or 1,000 mg daily for 4 months showed a 12% improvement in leg muscle strength and a 17% increase in aerobic endurance, along with a decrease in inflammatory markers. The product is currently marketed as Mitopure.
Study 2: HIIT and Mitophagy, Mayo Clinic, 2025
A team at the Mayo Clinic showed that after 12 weeks of HIIT training in older adults aged 65-80, the expression of mitophagy genes (including PINK1, Parkin, BNIP3) increased by about 65% in muscle biopsies. Concurrently, mitochondrial quality (average membrane potential) improved by 30%. High-intensity exercise is the most potent natural stimulator of mitophagy known to medicine.
Study 3: PINK1 Trial in Parkinson's, University of California, Los Angeles, 2024
A team in Los Angeles developed a small molecule (PINK1-001) that stabilizes PINK1 on the mitochondrial membrane even in the presence of a mutation. In mice with a Parkinson's model, the molecule reduced dopamine neuron loss by 58% and preserved motor function. A Phase 1 trial in humans began in 2025, with results expected in 2027.
Study 4: Fasting and Its Effect on Mitophagy, University of Copenhagen, 2023
Fasting for at least 16 hours increases mitophagy markers by 60% in human liver and muscle, through activation of AMPK and inhibition of mTOR. It is highly likely that this is why intermittent fasting improves metabolic function even without overall calorie reduction.
Study 5: Mitophagy Failure in Rare Diseases, NIH, 2024
A series of 17 rare metabolic diseases (including Leigh syndrome and MELAS syndrome) has been linked to specific mitophagy failure. In each, 40-80% fewer mitochondria in volume and 3-5 times more fragmented mitochondria were observed. The Countdown Grant focuses on these diseases as a regulatory entry point.
What About Heart Disease, Kidney Disease, and Chronic Diseases?
After the link to neurodegenerative diseases was clarified, researchers turned to the rest of the body. Heart failure is characterized by cardiomyocytes filled with damaged mitochondria. Studies in mice showed that activating mitophagy reduces heart infarct size by 30%.
Chronic kidney disease, impaired mitophagy in tubular cells is found in every biopsy from chronic kidney disease patients. Restoring mitophagy via urolithin A in animal models slowed progression to kidney failure.
Type 2 diabetes, pancreatic cells that produce insulin are highly dependent on mitochondria. Mitophagy failure causes these cells to lose glucose sensitivity and stop producing insulin. New drugs targeting mitophagy in the pancreas are in early research stages.
Cancer, the link here is complex. In early stages, normal mitophagy prevents cancer formation. But in advanced stages, some tumors rely on mitophagy to survive stress conditions and resist chemotherapy. Therefore, inhibiting mitophagy is being studied as a treatment for certain cancers.
Should We Start Taking a Supplement That Enhances Mitophagy?
As of 2026, there are several options with varying levels of evidence:
Urolithin A (Mitopure, 500-1,000 mg per day)
The best clinical evidence available for a mitophagy enhancer in humans. Price: 350-500 shekels per month. Particularly suitable for older adults with muscle weakness, sarcopenia, or general frailty. Mild side effects (stomach discomfort in 5-8% of patients). The main risk: no safety data beyond two years.
Spermidine (1-3 mg per day)
A polyamine naturally found in wheat germ, aged cheeses, and soy. Its evidence for mitophagy is thinner than that of urolithin A, but it comes at a low price and with excellent safety after thousands of years of dietary consumption.
NMN and NR (NAD+ Boosting)
NAD+ is required for normal mitophagy. Supplementing with NMN raises NAD+ by 30-40% and indirectly promotes mitophagy. Warning: A study from Washington University in 2024 showed that NMN may help resistant cancer cells survive treatment. Anyone with cancer risk factors should consult a doctor.
Physical Exercise
The cheapest intervention with the strongest evidence. 2-3 HIIT sessions per week increase mitophagy more than any molecule tested to date. The difference: physical exercise has the most modest side effects.
The Risk of Taking a Non-Targeted 'Mitophagy Enhancer'
One should not underestimate the possibility that excessive mitophagy could also be problematic. Neurons, for example, rely on mitochondria that last relatively long. Enhancing mitophagy beyond the physiological level could cause cells to lose essential mitochondria. A supplement is not a drug: it is advisable to start with a low dose and monitor.
What to Do Starting Today
- Add 2-3 HIIT sessions per week. The classic protocol: 4 intervals of 4 minutes at 85-95% of maximum heart rate, with 3 minutes of recovery between each. This is the most potent natural stimulator of mitophagy known to science.
- Eat pomegranates, walnuts, and raspberries, three times a week. They provide ellagitannins, the raw material that the microbiome will convert to urolithin A. In 30-40% of the population, the conversion by the microbiome is normal. For the rest, direct supplementation is preferable.
- Fast for 14-16 hours daily. For example, from 7:00 PM to 11:00 AM. Fasting activates mitophagy via AMPK and inhibition of mTOR. This is the cheapest and most natural way to increase the rate.
- Quality sleep of 7-8 hours. Mitophagy peaks during deep sleep. Poor sleep is akin to stopping the natural mechanism for removing damaged mitochondria.
- Consider a urolithin A supplement (Mitopure or a similar product) if you are over 50 or have signs of muscle weakness. 500 mg per day for 4 months is the proven clinical protocol.
- If there is a family history of Parkinson's, consult a neurologist about genetic testing for PINK1 and Parkin. Early detection of a mutation does not change treatment today but aids in monitoring.
The Broader Perspective
The Countdown Grant marks an important moment in aging medicine. For twenty years, mitophagy was an interesting biological concept studied by basic scientists in the lab. Now, following the success of urolithin A in humans, it is becoming a legitimate drug target attracting hundreds of millions of dollars in investment.
The deeper idea is that aging is not a static condition that needs to be 'fixed' all at once, but a dynamic process of cellular waste accumulation. Every day, the body produces damaged proteins, damaged mitochondria, and zombie cells. All healthy life depends on the efficiency of the cleaning systems. When they work, even at age 80, cells look relatively young. When they fail, even at age 50, the signs are visible.
But the most important message remains consistent: before looking for a supplement or drug, check if the natural mechanisms are working. Physical exercise, moderate fasting, long sleep, and a diet rich in phytochemicals activate the same mitophagy pathways that scientists are trying to mimic with molecules. The best anti-aging drug of 2026 is still the one without a patent.
References:
The Manila Times - Countdown Grant Explores How Cells Remove Damaged Mitochondria (2026-05-15)
💬 תגובות (0)
היו הראשונים להגיב על המאמר.